Stocks making the biggest moves midday: NetApp, Intel, Apple, Doximity, Verisk Analytics & more
Check out some of the companies making the biggest moves midday: MarineMax — The boat and yacht retailer soared 46% after agreeing to be sold to Blackstone Infrastructure’s Safe Harbor Marinas for $53 a share in cash, or $1.5 billion. The deal’s expected to close by the end of 2026. Varex Imaging — The imaging component maker climbed 48% after Teledyne Technologies agreed to buy Varex for $18.90 a share in cash. The deal is expected to close in early 2027. Teledyne rose a fraction. Artificial intelligence infrastructure — Stocks tied to artificial intelligence infrastructure slid. The Global X Data Center & Digital Infrastructure ETF (DTCR) lost 1%. Corning fell more than 3%. Photonics stocks Coherent and Lumentum dropped 12% and more than 6% respectively. Doximity — Shares of the digital medical platform fell 5%. On Friday, the stock surged more than 32% after CEO Jeffrey Tangney said the company was seeing huge margins on its artificial intelligence search tool. NetApp – The data storage company gained 6% after Morgan Stanley lifted it to equal weight from underweight. “Improving storage fundamentals support higher earnings estimates, although valuation at peak P/E already reflects meaningful credit for this improving outlook,” wrote analyst Erik Woodring. Verisk Analytics — The data analytics company tumbled more than 5% after a Delaware judge on Friday ruled it must proceed with a $2.35 billion acquisition of AccuLynx. Verisk previously terminated a deal in December because a Federal Trade Commission review of the merger was not completed by the transaction’s termination date. Apple — The iPhone maker company dipped 2% after Jefferies downgraded Apple to underperform from hold. According to the bank’s supply chain checks, analysts have concluded than an all-glass iPhone by Apple , something the company has never publicly announced, appears to be canceled. That puts pressure on Apple, which is trying to sell more expensive devices to combat the rising cost of memory. Everpure — The data storage provider surged 9% after Morgan Stanley and Susquehanna raised their investment recommendations. Berkshire Hathaway — The Geico insurance owner rose almost 2% after saying Saturday it saw operating earnings grow 16% in the second quarter. Manufacturing, service, and retailing earnings saw strong growth, as did energy profits. Insurance was weaker, with investment income declining 9%. Intel — The chipmaker fell nearly 3% after announcing it will offer $15 billion in common stock . Intel plans to use the cash for general corporate purposes, which may include capital expenditures and working capital. Monday.com – The provider of work management software dropped more than 6% after guidance disappointed Wall Street. Monday.com sees revenue in a range of $368 million to $370 million for the current quarter, while the FactSet consensus called for $372.8 million. Guidance for full-year revenue was roughly in line with expectations. Ebay — The online retailer dropped 3% after Bloomberg said GameStop is considering abandoning its takeover offer. GameStop’s unsolicited bid was originally rejected by eBay in May , when it was called “neither credible nor attractive.” Hewlett Packard Enterprise — Shares rose 4% after Morgan Stanley upgraded HPE to overweight from equal-weight. Analysts said HPE has an attractive risk/reward profile, and that the market is underappreciating the asymmetry between HPE’s earnings power and valuation. Archer Aviation — The aerospace company surged almost 8% after agreeing to acquire three Boeing subsidiaries. Boeing is also taking an undisclosed stake in Archer. Archer CEO Adam Goldstein said the acquisitions will help the company diversify revenues and expand. Boeing gained a fraction. AbCellera Bologics – The biotech soared 43% after reporting strong Phase 2 clinical results for its medication to treat hot flashes caused by menopause. “Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single dose,” AbCellera said. N-Able — The software maker plunged more than 37% after N-able gave disappointing current quarter guidance. N-able sees third quarter revenue of about $135 million, short of the FactSet consensus estimate of almost $142 million. Adjusted EBITDA of $41.0 million to $42.0 million also missed the $46.3 million consensus estimate. Sionna Therapeutics – The biotech plunged 92% after its cystic fibrosis drug failed to meet key endpoints in a proof-of-concept trial. Sionna said it was disappointed with the results and that it would not advance the drug as an add-on to standard of care. — With additional reporting by Davis Giangiulio, Darla Mercado, Alex Harring and Sarah Min
